Orally disintegrating tablets of atomoxetine
US8747895B2 · kind B2 · utility
15Cited by
185References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 9, 2005 |
| Grant date | Jun 10, 2014 |
| Priority date | — |
| Expiry date | Nov 7, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/5078
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A coated multi-particulate pharmaceutical dosage form such as an orally disintegrating tablet (ODT) presentation for delivering atomoxetine or a pharmaceutically acceptable salt thereof, a selective norepinephrine reuptake inhibitor indicated for the treatment of ADHD, into the body to maintain a therapeutically effective amount of atomoxetine in the plasm. The dosage form may comprise one or more populations of coated atomoxetine-containing particles (beads, pellets, granules etc.) providing a pre-designed rapid release profile after a predesigned lag-time of about 0 to 6 hours following oral administration.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.